Clinical Trials Logo

Cicatrix, Hypertrophic clinical trials

View clinical trials related to Cicatrix, Hypertrophic.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05478551 Active, not recruiting - Scar Clinical Trials

Randomized Controlled Trial Examining the Efficacy of Botulinum Toxin in Biopsy Scar Minimization

Start date: June 1, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

The proposed study seeks to evaluate the scar reduction capacity of BTA on excision/biopsy wounds compared to the control (normal saline) in a double-blinded randomized control trial. It will expand upon previous studies that have already demonstrated the safety and good tolerance profile of BTA. We will be conducting a split-scar study/study involving two biopsy sites in a singular patient, allowing them to serve as their own control. In keeping with the results from previously conducted studies, we hypothesize that the wounds treated with BTA will have significantly less evidence of scar formation than those sites treated with normal saline.

NCT ID: NCT04756882 Active, not recruiting - Clinical trials for Hypertrophic Scarring

Clinical Evaluation of the Efficacy OF Botulinum Toxin A for Improving Facial Scars

Start date: November 18, 2020
Phase: Phase 2/Phase 3
Study type: Interventional

Background: Scars widen when the overlying musculature pulls apart suture lines. Because Botulinum Toxin A (BTA) is known to prevent fibroblast proliferation and it also induces temporary muscle paralysis, the purpose of this current study is to evaluate the beneficial effects of Botulinum toxin type A (BTA) on scar formation. Aim of this study: The aim of this study is to evaluate the efficacy and safety of early postoperative Botulinum Toxin type A (BTA) injection on improving vertical or oblique facial surgical scars. Materials and methods: Patients with vertical or oblique forehead lacerations, treated by primary closure, will be enrolled in this study and randomized into two groups: One group (n =6) will receive BTA injection within 5 days of primary closure and the other group (n = 6) will receive no further treatment. Vancouver scar scale (VSS) Scores and wound width will be determined at the 1, 3 and 6 months follow-up visits, along with clinical photographs. Results: Data will be collected, tabulated and statically analyzed. Key words: Botulinum Toxin Type A; facial scarring; wound healing; scar maturation

NCT ID: NCT04532840 Active, not recruiting - Hypertrophic Scars Clinical Trials

Effect of Cryotherpy on Hypertrophic Scar

Start date: April 15, 2019
Phase: Phase 2/Phase 3
Study type: Interventional

Purpose of the study: The purpose of the study is to evaluate the therapeutic effect of cryotherpy in treating hypertrophic scar. It will be hypothesized that: Cryotherapy may not have an effect on hypertrophic scar.

NCT ID: NCT04389619 Active, not recruiting - Hypertrophic Scars Clinical Trials

Fractional Microneedling RF vs Intralesional Steroid With & Without Microneedling in Hypertrophic Scars

Start date: May 10, 2020
Phase: N/A
Study type: Interventional

Comparing between the effect of Fractional Microneedling Radiofrequency Versus Intralesional Steroid Injection with and without Microneedling on Tissue levels of PDGF & CTGF in Hypertrophic Scars

NCT ID: NCT02246465 Active, not recruiting - Hypertrophic Scar Clinical Trials

A Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Revised Hypertrophic Scars

Start date: July 2014
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the effectiveness of RXI-109 in reducing the recurrence of hypertrophic scar formation following elective revision of a pre-existing hypertrophic scar.

NCT ID: NCT01736969 Active, not recruiting - Hypertrophic Scar Clinical Trials

A Substantial Equivalence Study of RD04723 and Predicate Device

Start date: August 2012
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether a developmental formulation is substantially equivalent to the predicate device in the treatment of hypertrophic and keloid scars.

NCT ID: NCT01113125 Active, not recruiting - Hypertrophic Scars Clinical Trials

Scars After Central Venous Catheters

Start date: March 2010
Phase: Phase 3
Study type: Interventional

Most children with cancer need a central venous catheter. These catheters are typically placed on the anterior thorax, where the risk of hypertrophic scarring and keloid development is greatly enhanced. A significant part of the children who have survived childhood cancer are troubled by their scars. Topical glucocorticoid treatment is known to induce a reduction of the collagen in the connective tissue. The investigators hypothesize that treatment with topical glucocorticoids for one week before and three weeks after removal of a central venous catheter, will reduce the formation of hypertrophic scarring and keloid development in children.

NCT ID: NCT01004536 Active, not recruiting - Clinical trials for Hypertrophic Cicatrix

An Investigator-blind Multi-center Prospective Study for the Efficacy and Safety of Silicon Gel (Dermatix)

Start date: October 2010
Phase: Phase 4
Study type: Interventional

Silicone gel is a self-drying silicone polymer that forms thin film after application onto the skin. Because silicone film is a medical device, silicone gel is also regarded as a medical device. Silicone gel has been on the market for many years for the management of scar in the phase of treatment as well as in the phase of prevention. In contrast to other methods that are expensive, invasive or inconvenient, silicone gel is convenient, non-invasive and also reasonably priced. However, the number of well-designed clinicial trials for efficacy and safety are not enough to provide robust evidences in making clinical decisions for scar management options. In a prospective, multi-center, investigator-blind randomized half-split study for patients undergoing cesarean sections, the investigators attempt to provide valid information for the efficacy and safety of silicone gel in the prevention phase of scar.

NCT ID: NCT00849004 Active, not recruiting - Hypertrophic Scars Clinical Trials

Prevention of Hypertrophic Scars or Keloids

RCT
Start date: March 2009
Phase: N/A
Study type: Interventional

Keloids and hypertrophic scars are not major illness. However, their effects can be from causing pain and itch which substantially interfere daily activity to as severe as causing deformity and other functional impairment. For standard surgical wounds, taking median sternotomy wounds from open heart surgery and lower abdominal wounds from gynecological wounds for example, the incidence of these problems can be from 10% to 60%. To prevent or treat these problems, physicians have used many modalities. One of the most convenient, most cost-effective and most non-invasive methods for patients is using dressings like silicone sheets, silicone gels or paper tapes, which is on the list of 1st line choices of an international recommendation. According to a literature review, most of the previous studies on similar topics are either of small sample size, on non-standard wounds or comparisons between wounds on different patient groups. The methodologies of previous studies are thus not vigorous enough. To get the highest level of evidence on selecting the best dressings for preventing and treating keloids and hypertrophic scars, we will recruit about 75 patients and apply two selected dressings on each halves of their standard surgical wounds to compare their differences. The investigators hope the result of this study can help us find the best modality to use and can contribute to the welfare of our future patients.